## SOLV: Solventum Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.1% below STRENGTH zone (3.0-6.0%); PEG 1.43 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($77.26)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Strong Tower Advisory Services Buys 16,851 Shares of Solventum Corporation $SOLV**
- Source: MarketBeat | 20251224T130856 | Somewhat-Bullish | Relevance: 100%
- Strong Tower Advisory Services increased its stake in Solventum Corporation (NYSE:SOLV) by 20.5% in the third quarter, acquiring an additional 16,851 shares to now hold 99,169 shares valued at approximately $7.24 million. Solventum recently exceeded quarterly earnings estimates and announced a $1 billion share repurchase plan. The stock currently holds a "Hold" consensus rating from analysts with an average target price of $87.00.

**2. Thermo Fisher Scientific (TMO) Stock: Key News, Analyst Forecasts, and Catalysts to Watch Before the Market Opens on Dec. 26, 2025**
- Source: ts2.tech | 20251226T014349 | Somewhat-Bullish | Relevance: 70%
- This article provides a comprehensive overview of Thermo Fisher Scientific (TMO) stock, covering major news, analyst forecasts, and key catalysts influencing its performance before the market opens on December 26, 2025. It details recent acquisitions, capital return strategies, operational results, product developments, and Wall Street's outlook. The report emphasizes the company's strategic M&A, bioprocessing expansion, and pharma services growth as drivers of its evolving growth profile.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | BTIG | $100 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | BTIG | up | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 0 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+5.3%)
- Independent Franchis: 7.4% (+27.2%)
- Blackrock Inc.: 5.9% (+6.1%)
- Trian Fund Managemen: 4.9% (0.0%)
- State Street Corpora: 3.6% (+1.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.0% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.43 suggests fair value with growth premium. Forward P/E 12.6x stretched relative to 6% growth. Quality metrics strong (ROE 37%, margin 18%). Institutional flow bullish (8 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.0B |
| Beta | 1.00 |
| 52W Range | $60.70 - $88.20 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.43 |
| Forward P/E | 12.6 |
| Current P/E | 13.4 |
| YoY Growth | 5.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.1% to -2.1% (-2.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.1pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-0.63), momentum weakening. RSI neutral at 50. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.07% (CS: 22) | Weak |
| RSI_14 | 49.8 | Neutral |
| MACD Histogram | -0.63 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 1.040x | Above |
| vs SMA200 | 1.093x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $80.44
- **Stop Loss:** $77.26 (4.0% risk)
- **Target:** $83.62 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 415
- **Position Value:** $33,382.60
- **Portfolio %:** 33.38%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-26 (Est: $1.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $1.50 | +4.7% |
| 2025Q2 | $1.45 | $1.69 | +16.2% |
| 2025Q1 | $1.22 | $1.34 | +9.7% |
| 2024Q4 | $1.31 | $1.41 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*